Brighter: Funding, Investors & Team (Sep 2026)

Data-driven solutions for smarter treatment of chronic conditions. Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Tackling diabetes first. Brighter is currently focused on treating the global diabetes epidemic by launching Actiste® Diabetes Management as a Service. https://actiste.com/ The Actiste device is based on patented technology for the remote monitoring and collection of data on specified bio-markers and volumes of medication injected. We believe this data-centric approach is key to providing smarter care for both diabetes and other chronic conditions too. Why Actiste? A video explaining the diabetes care service Actiste: https://youtu.be/qLWfTUbl3eM Brighter’s business model includes out-licensed rights to its platform. A business-critical part of Brighter’s operations involves continuous IP portfolio development—via its own applications and in-licensing (for example, the micro-needle technology in-licensing that Brighter acquired for blood sugar monitoring).

Brighter has raised $10.0M across 1 round on record. The most recent is a Post-IPO Debt of $10.0M announced in Aug 2022.

Brighter's most recent funding round on record is a Post-IPO Debt of $10.0M, announced in Aug 2022.

Henrik Norstrom is listed as CEO at Brighter.

Brighter is based in Kista, Stockholms Lan, Sweden.

Brighter is in the 51-100 employee band.

Brighter's latest round of $10.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.